Nelarabine

$ 1.00 /1kg

Min. Order1kg
Purity99%
Cas No121032-29-9
Supply AbilityCustomized
Update time2019-07-06

career henan chemical co

7YR

China

Chemical Properties

Product Name	Nelarabine
CAS No	121032-29-9
EC-No	1806241-263-5
Min. Order	1kg
Purity	99%
Supply Ability	Customized
Release date	2019/07/06

SP237

Nelarabine Basic information

Physical properties Developed by GlaxoSmithKline Pharmacology and pharmacokinetics Clinical trials Usage and dosage Note

Product Name:	Nelarabine
Synonyms:	NELARABINE;Nelzarabine [USAN];Nelzarabine;9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine;(2R,3R,4S,5R)-2-(2-aMino-6-Methoxy-9H-purin-9-yl)-5-(hydroxyMethyl)-tetrahydrofuran-3,4-diol;Nelarabine (Arranon);506u;9-β-D-Arabinofuranosyl-6-Methoxy-9H-purin-2-aMine
CAS:	121032-29-9
MF:	C11H15N5O5
MW:	297.27
EINECS:	1806241-263-5
Product Categories:	Bases & Related Reagents;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;5g,10g,25g,100g;ARRANON;Anti-cancer&immunity;API;Inhibitors
Mol File:	121032-29-9.mol

Nelarabine Chemical Properties

Melting point	209-217°
alpha	D20 +55.9° (c = 0.27 in DMF)
CAS DataBase Reference	121032-29-9(CAS DataBase Reference)

Safety Information

MSDS Information

Nelarabine Usage And Synthesis

Physical properties

White or almost white crystalline powder. This product is slightly soluble in water, the solubility in water is about 8-9mg/ml (25 ℃, PH = 4~10).

Developed by GlaxoSmithKline

Nelarabine is a prodrug for deoxyguanosine analogue ——9-beta-D-arabinofuranosyl guanine (ara-G). Nelarabine demethylates in the role of adenosine deaminase (ADA) and turns into ara-G. Then, It turns into active ara-G triphosphate (ara-GTP) in the role of the deoxyguanosine kinase and deoxycytidine kinase and under the action of the monophosphorylation pathway. Ara-GTP can accumulate in leukemia cells, and bind to DNA to inhibit DNA synthesis, and accelerate leukemia cell death. In addition, the anti-cancer mechanism of Nelarabine may also be related to its cytotoxicity and somatic toxicity.
Nelarabine was first successfully developed by GlaxoSmithKline. On October 28, 2005 under the approval of the US Food and Drug Administration, it became a new drug for curing T-cell acute lymphoblastic leukemia (T-ALL) and T-Cells lymphoblasticlymphoma (T-LBL) which are resistant to at least two types of chemotherapy regimens or relapsed after initial treatment. This new drug officially listed in the United States in 2006. This product didn’t apply for patent and administrative protection in China, so the development of this product does not exist intellectual property issues.

Company Profile Introduction

Recommended supplier

Send Inquriy

Nelarabine

Company Profile Introduction

You may like

Recommended supplier